In this section More on this Topic

Innovations in Drug Development - September 9, 2015

Share:
Linked In Print Email

A. James Clark Distinguished Professorship in Molecular Genetics
Innovations in Drug Development: How Children’s National is Taking a Leadership Role in Faster, Better, and Cheaper Drugs 

Presented by: 

Eric Hoffman, PhD
Director, Research Center for Genetic Medicine, Children’s National
Professor and Chairman, Department of Integrative Systems Biology, George Washington University
Co-Founder, ReveraGen Biopharma

Give Act

Invest in future cures for some of life's most devastating diseases

See other ways to give

Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you.

Share your birthday with a child. Celebrate your life, and give a chance to someone who desperately wants to have as many as you. Make it happen

You Might Also Be Interested In:

Brain Tumor Institute

We bring together a comprehensive team of pediatric oncology and neurology experts, giving children with brain tumors effective, personalized care.

Rare Diseases Expert Talks about Research in Duchenne Treatments

Eric Hoffman, PhD, discusses the progress in discovering novel treatments for Duchenne muscular dystrophy with the Washington Post.

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

A novel anti-inflammatory in development for the chronic treatment of Duchenne muscular dystrophy by ReveraGen BioPharma,  a private spin-off company from Children’s National Health System, has received $2 million from four nonprofit organizations.

New Muscular Dystrophy Treatment Shows Promise in Early Study Led by Children’s National

A preclinical study led by researchers at Children’s National Medical Center has found that a new oral drug shows early promise for the treatment of Duchenne muscular dystrophy (DMD).